Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of PRTX-100 in Healthy Adult Volunteers

This study has been completed.
Sponsor:
Information provided by:
Protalex, Inc.
ClinicalTrials.gov Identifier:
NCT00517855
First received: August 15, 2007
Last updated: May 1, 2008
Last verified: May 2008

August 15, 2007
May 1, 2008
June 2007
September 2007   (final data collection date for primary outcome measure)
  • Pharmacokinetics [ Time Frame: Various timepoints over 14 days ]
  • Safety (assessed by adverse events, clinical lab tests, vital signs, ECG, physical exam) [ Time Frame: Various timepoints over 60 days ]
Same as current
Complete list of historical versions of study NCT00517855 on ClinicalTrials.gov Archive Site
  • Immunogenicity [ Time Frame: Various timepoints over 60days ]
  • Pharmacodynamic markers of drug effect [ Time Frame: Various timepoints over 60 days ]
Same as current
Not Provided
Not Provided
 
Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of PRTX-100 in Healthy Adult Volunteers
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single-Dose Escalation Study of the Safety and Pharmacokinetics of Intravenous Doses of PRTX-100 in Healthy Adult Subjects

This study is the second human clinical study with PRTX-100. It is designed to assess the safety of a single intravenous (IV) dose of PRTX-100, as well as, how the drug is eliminated from the blood after dosing. Additionally, this study provides an opportunity to monitor immune system response to PRTX-100.

A total of 20 healthy subjects will be enrolled into one of two dosing cohorts. Each dosing cohort will consist of 10 subjects. Within each cohort, subjects will be randomized to clinical trial material (CTM) (PRTX-100 or placebo) such that 8 subjects receive PRTX-100 and 2 subjects receive placebo. The PRTX-100 doses to be assessed in an ascending fashion are: 0.30 mcg/kg and 0.45 mcg/kg. Dosing of Cohort 2 will occur after the Investigator reviews Day 0-14 safety data and confers with the Sponsor Medical Monitor.

Subjects will be confined to the clinical pharmacology research unit for 5 days following dosing. Each cohort will have safety, pharmacokinetic, and pharmacodynamic assessments over the 5-day post-dose period. Subjects will also have follow-up assessments at 6, 7, 10 (±1), 14 (±1), 30 (±2), and 60 (±2) days post-dose.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Healthy Volunteers
Biological: PRTX-100 (Staphylococcal protein A)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
September 2007
September 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Able to provide written, informed consent
  • Subjects in good health as determined by medical history, physical exam, standard safety laboratory tests, electrocardiogram (ECG) and vital signs
  • Body Mass Index (BMI) within the range of 18.5-32 kg/m2
  • Normotensive, defined as systolic blood pressure less than or equal to 150 mmHg and diastolic blood pressure less than or equal to 90 mmHg

Exclusion Criteria:

  • Positive IgE anti-SpA titer on screening visit
  • Male and female subjects unwilling to use acceptable forms of birth control throughout the study (acceptable forms include hormonal contraceptives used for at least 2 months prior to the screening visit, condom plus spermicide, cervical cap plus spermicide, diaphragm plus spermicide, or intrauterine device plus spermicide)
  • Pregnant (β-hCG serum pregnancy test positive) or nursing (lactating) female subjects
  • Clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s), as determined by the investigator or designee
  • Past medical history of deep venous thrombosis or thromboembolic disease, stroke, myocardial infarction, recurrent fetal loss, or prior diagnosis of Protein C deficiency or of factor V Leyden genotype
  • Past history of vasculitis or autoimmune disease
  • Clinical signs or symptoms of acute or resolving viral or bacterial infection
  • History of atopic dermatitis or asthma
  • History of current hepatitis or carriers of hepatitis B and/or hepatitis C (Hepatitis B surface antigen [HbsAg] positive or IgM antibodies to Hepatitis C [anti Hepatitis C IgM]).
  • History of AIDS or determined HIV seropositive at screening
  • Any disorder that would interfere with the absorption, distribution, metabolism, or excretion of drugs
  • Clinically significant abnormalities in screening laboratory tests (hematology, chemistry, urinalysis)
  • Positive urine drug test at screening or baseline (e.g., cocaine, amphetamines, barbiturates, opiates, benzodiazepines, etc.)
  • Positive blood test for ethanol at screening or baseline
  • Use of dietary supplements or prescription (with the exception of hormonal contraceptives), herbal, and over-the-counter medication(s) (with the exception of acetaminophen less than or equal to 1000 mg/day) within the 10 days prior to study Day 1
  • Unable to refrain from tobacco or nicotine product use during the period of study confinement
  • Donation of blood or plasma within 30 days prior to dosing
  • Use of (an) investigational drug(s) within the 30 days or 5 half-lives (whichever is longer) prior to Day 1
Both
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00517855
PRTX-100B-102
No
Not Provided
Protalex, Inc.
Not Provided
Principal Investigator: Charles H Ballow, PharmD Buffalo Clinical Research Center
Protalex, Inc.
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP